Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
9.15
+0.16 (1.78%)
At close: Oct 28, 2026, 4:00 PM EDT
9.02
-0.13 (-1.42%)
After-hours: Oct 28, 2026, 7:30 PM EDT
Contineum Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Contineum Therapeutics stock has a consensus rating of "Buy" and an average price target of $22.14. The average 1-year stock price forecast is 141.97% higher than the current stock price, while the lowest is $14 (+53.01%) and the highest is $30 (+227.87%).
Price Target: $22.14 (+141.97%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Maintains $24 → $30 | Buy | Maintains | $24 → $30 | +227.87% | Oct 14, 2026 |
| Robert W. Baird | Robert W. Baird | Hold Downgrades $19 → $14 | Hold | Downgrades | $19 → $14 | +53.01% | Oct 14, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $17 | Hold | Maintains | $17 | +85.79% | Oct 12, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $29 → $28 | Buy | Reiterates | $29 → $28 | +206.01% | Oct 12, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 30, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.70
from -2.17
EPS Next Year
-1.92
from -1.70
EPS and Forward PE are based on non-GAAP adjusted numbers.